Christopher Gignoux
Concepts (384)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genetics, Population | 32 | 2025 | 200 | 3.210 |
Why?
| Genome-Wide Association Study | 39 | 2025 | 1337 | 2.160 |
Why?
| Polymorphism, Single Nucleotide | 52 | 2025 | 2065 | 2.050 |
Why?
| Genome, Human | 24 | 2023 | 392 | 1.950 |
Why?
| Genetic Variation | 18 | 2025 | 934 | 1.770 |
Why?
| Genetic Predisposition to Disease | 24 | 2024 | 2266 | 1.410 |
Why?
| Genomics | 18 | 2024 | 716 | 1.240 |
Why?
| Models, Genetic | 12 | 2025 | 590 | 1.220 |
Why?
| Precision Medicine | 4 | 2024 | 383 | 1.010 |
Why?
| Asthma | 19 | 2019 | 2215 | 1.000 |
Why?
| Multifactorial Inheritance | 9 | 2024 | 149 | 0.960 |
Why?
| Genetics, Medical | 5 | 2023 | 22 | 0.930 |
Why?
| Biological Specimen Banks | 5 | 2024 | 96 | 0.810 |
Why?
| Transcriptome | 5 | 2024 | 881 | 0.800 |
Why?
| Pharmacogenetics | 2 | 2021 | 171 | 0.800 |
Why?
| Gastritis | 1 | 2023 | 97 | 0.770 |
Why?
| Enteritis | 1 | 2023 | 94 | 0.760 |
Why?
| Desogestrel | 1 | 2021 | 46 | 0.720 |
Why?
| Haplotypes | 21 | 2022 | 471 | 0.710 |
Why?
| Human Migration | 6 | 2021 | 21 | 0.660 |
Why?
| Gene Flow | 8 | 2020 | 76 | 0.620 |
Why?
| Chromosomes, Human, Pair 18 | 1 | 2018 | 9 | 0.620 |
Why?
| Smad2 Protein | 1 | 2018 | 34 | 0.610 |
Why?
| Eosinophilic Esophagitis | 1 | 2023 | 318 | 0.610 |
Why?
| Humans | 125 | 2025 | 128524 | 0.600 |
Why?
| Genotype | 24 | 2025 | 1831 | 0.600 |
Why?
| Gene Frequency | 13 | 2025 | 504 | 0.590 |
Why?
| Chromosome Mapping | 11 | 2023 | 505 | 0.500 |
Why?
| Population | 2 | 2014 | 33 | 0.480 |
Why?
| Population Growth | 2 | 2012 | 9 | 0.470 |
Why?
| DNA, Mitochondrial | 6 | 2016 | 192 | 0.470 |
Why?
| Metagenomics | 4 | 2023 | 153 | 0.460 |
Why?
| Indians, North American | 7 | 2021 | 600 | 0.430 |
Why?
| Receptors, KIR | 5 | 2022 | 96 | 0.430 |
Why?
| Mexican Americans | 7 | 2023 | 113 | 0.420 |
Why?
| Agriculture | 2 | 2011 | 92 | 0.420 |
Why?
| Evolution, Molecular | 6 | 2021 | 467 | 0.410 |
Why?
| Genetic Loci | 7 | 2019 | 274 | 0.380 |
Why?
| Exome | 5 | 2022 | 220 | 0.380 |
Why?
| Alleles | 12 | 2025 | 845 | 0.350 |
Why?
| Molecular Epidemiology | 3 | 2023 | 63 | 0.350 |
Why?
| Quantitative Trait Loci | 6 | 2024 | 356 | 0.350 |
Why?
| Indians, South American | 2 | 2020 | 22 | 0.350 |
Why?
| Pedigree | 3 | 2021 | 485 | 0.340 |
Why?
| Genetic Association Studies | 3 | 2022 | 359 | 0.330 |
Why?
| Computational Biology | 3 | 2023 | 597 | 0.330 |
Why?
| Population Groups | 2 | 2020 | 57 | 0.320 |
Why?
| Phenotype | 13 | 2024 | 3050 | 0.320 |
Why?
| Linkage Disequilibrium | 9 | 2023 | 256 | 0.310 |
Why?
| Proteome | 2 | 2024 | 431 | 0.300 |
Why?
| Kidney Diseases | 2 | 2025 | 368 | 0.300 |
Why?
| Skin Pigmentation | 2 | 2018 | 48 | 0.290 |
Why?
| Selection, Genetic | 4 | 2019 | 250 | 0.290 |
Why?
| DNA Methylation | 3 | 2024 | 604 | 0.280 |
Why?
| Receptors, KIR2DL1 | 2 | 2018 | 18 | 0.270 |
Why?
| Female | 45 | 2024 | 68127 | 0.270 |
Why?
| Gene-Environment Interaction | 3 | 2023 | 185 | 0.270 |
Why?
| Genetic Markers | 7 | 2023 | 339 | 0.270 |
Why?
| Environmental Exposure | 3 | 2017 | 464 | 0.260 |
Why?
| Mexico | 8 | 2023 | 190 | 0.260 |
Why?
| Phylogeography | 5 | 2020 | 49 | 0.260 |
Why?
| Colorado | 4 | 2024 | 4392 | 0.260 |
Why?
| Minority Groups | 2 | 2019 | 251 | 0.250 |
Why?
| Delivery of Health Care | 2 | 2023 | 892 | 0.240 |
Why?
| Phylogeny | 7 | 2022 | 846 | 0.240 |
Why?
| Gene Expression Profiling | 3 | 2020 | 1687 | 0.230 |
Why?
| Puerto Rico | 8 | 2021 | 52 | 0.230 |
Why?
| Killer Cells, Natural | 4 | 2021 | 425 | 0.230 |
Why?
| Bivalvia | 1 | 2024 | 6 | 0.230 |
Why?
| Risk Factors | 16 | 2024 | 9727 | 0.230 |
Why?
| Heterozygote | 3 | 2021 | 266 | 0.220 |
Why?
| Male | 42 | 2024 | 62883 | 0.220 |
Why?
| Chromosomes, Human, Pair 6 | 3 | 2014 | 52 | 0.220 |
Why?
| Genes, MHC Class I | 2 | 2021 | 33 | 0.220 |
Why?
| Young Adult | 12 | 2022 | 12320 | 0.210 |
Why?
| Thyroid Nodule | 1 | 2024 | 55 | 0.210 |
Why?
| Long QT Syndrome | 1 | 2024 | 67 | 0.210 |
Why?
| Algorithms | 3 | 2023 | 1616 | 0.200 |
Why?
| Glaucoma, Open-Angle | 1 | 2024 | 101 | 0.200 |
Why?
| Software | 2 | 2025 | 610 | 0.200 |
Why?
| Proteins | 2 | 2022 | 936 | 0.200 |
Why?
| Receptors, KIR3DS1 | 1 | 2022 | 6 | 0.200 |
Why?
| Case-Control Studies | 10 | 2024 | 3326 | 0.200 |
Why?
| Receptors, KIR3DL1 | 1 | 2022 | 17 | 0.190 |
Why?
| Immunoglobulin E | 2 | 2014 | 329 | 0.190 |
Why?
| Emigration and Immigration | 3 | 2013 | 50 | 0.190 |
Why?
| Myocardial Ischemia | 1 | 2023 | 249 | 0.190 |
Why?
| Demography | 5 | 2018 | 277 | 0.190 |
Why?
| Jews | 1 | 2021 | 19 | 0.190 |
Why?
| C-Reactive Protein | 1 | 2024 | 396 | 0.190 |
Why?
| Collagen Type VII | 1 | 2021 | 25 | 0.190 |
Why?
| Computer Simulation | 6 | 2025 | 939 | 0.180 |
Why?
| Epidermolysis Bullosa Dystrophica | 1 | 2021 | 38 | 0.180 |
Why?
| Pharmacogenomic Variants | 1 | 2021 | 35 | 0.180 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 34 | 0.180 |
Why?
| History, Medieval | 3 | 2021 | 44 | 0.180 |
Why?
| Electrocardiography | 1 | 2024 | 607 | 0.180 |
Why?
| Drug Implants | 1 | 2021 | 82 | 0.180 |
Why?
| Indians, Central American | 1 | 2020 | 5 | 0.180 |
Why?
| Adolescent | 18 | 2021 | 20213 | 0.170 |
Why?
| Latin America | 2 | 2018 | 84 | 0.170 |
Why?
| Population Health | 1 | 2021 | 45 | 0.170 |
Why?
| Reference Standards | 1 | 2020 | 170 | 0.170 |
Why?
| Thyroid Neoplasms | 1 | 2024 | 311 | 0.170 |
Why?
| Pre-Eclampsia | 1 | 2022 | 183 | 0.170 |
Why?
| Self Report | 2 | 2021 | 801 | 0.170 |
Why?
| Adaptation, Biological | 1 | 2020 | 56 | 0.170 |
Why?
| Lipase | 1 | 2020 | 64 | 0.160 |
Why?
| Data Interpretation, Statistical | 1 | 2021 | 335 | 0.160 |
Why?
| Human Genetics | 1 | 2019 | 2 | 0.160 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2024 | 2430 | 0.160 |
Why?
| Inflammatory Bowel Diseases | 1 | 2023 | 312 | 0.160 |
Why?
| Triglycerides | 2 | 2023 | 524 | 0.160 |
Why?
| Apolipoprotein L1 | 1 | 2018 | 13 | 0.160 |
Why?
| Geographic Mapping | 1 | 2019 | 20 | 0.160 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2017 | 756 | 0.160 |
Why?
| Antiporters | 1 | 2018 | 22 | 0.150 |
Why?
| Liver Diseases | 1 | 2021 | 285 | 0.150 |
Why?
| Aged | 11 | 2024 | 21971 | 0.150 |
Why?
| Europe | 5 | 2020 | 362 | 0.150 |
Why?
| Coronary Artery Disease | 2 | 2023 | 677 | 0.150 |
Why?
| Obesity | 2 | 2023 | 2860 | 0.150 |
Why?
| Chromosomes, Human, Y | 2 | 2008 | 20 | 0.150 |
Why?
| HLA-C Antigens | 1 | 2018 | 35 | 0.150 |
Why?
| Primates | 1 | 2019 | 118 | 0.150 |
Why?
| Collagen Diseases | 1 | 2017 | 6 | 0.140 |
Why?
| Fibrillar Collagens | 1 | 2017 | 14 | 0.140 |
Why?
| United States | 15 | 2021 | 13876 | 0.140 |
Why?
| Atherosclerosis | 1 | 2022 | 405 | 0.140 |
Why?
| Microbiota | 2 | 2023 | 720 | 0.140 |
Why?
| Dermatitis, Atopic | 1 | 2021 | 321 | 0.140 |
Why?
| Kidney | 1 | 2025 | 1305 | 0.140 |
Why?
| Epistasis, Genetic | 1 | 2017 | 71 | 0.140 |
Why?
| Apolipoprotein A-V | 1 | 2017 | 3 | 0.140 |
Why?
| Weight Gain | 1 | 2021 | 505 | 0.140 |
Why?
| Feasibility Studies | 1 | 2021 | 860 | 0.140 |
Why?
| Gene Pool | 2 | 2013 | 5 | 0.140 |
Why?
| Saliva | 2 | 2020 | 205 | 0.140 |
Why?
| Adult | 16 | 2024 | 35315 | 0.140 |
Why?
| History, Ancient | 3 | 2013 | 52 | 0.140 |
Why?
| Patient Acceptance of Health Care | 1 | 2023 | 764 | 0.140 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2020 | 259 | 0.130 |
Why?
| Homozygote | 3 | 2023 | 191 | 0.130 |
Why?
| Language | 2 | 2011 | 283 | 0.130 |
Why?
| Women's Health | 1 | 2019 | 363 | 0.130 |
Why?
| Colorectal Neoplasms | 1 | 2023 | 753 | 0.130 |
Why?
| Research Design | 1 | 2022 | 1038 | 0.130 |
Why?
| Colombia | 3 | 2021 | 36 | 0.120 |
Why?
| Social Class | 2 | 2013 | 259 | 0.110 |
Why?
| Genealogy and Heraldry | 1 | 2013 | 5 | 0.110 |
Why?
| Premature Birth | 1 | 2018 | 311 | 0.110 |
Why?
| Africa, Southern | 3 | 2018 | 8 | 0.110 |
Why?
| Minority Health | 1 | 2013 | 20 | 0.110 |
Why?
| Ikaros Transcription Factor | 1 | 2014 | 21 | 0.110 |
Why?
| Health Surveys | 1 | 2016 | 492 | 0.110 |
Why?
| Pandemics | 1 | 2022 | 1487 | 0.110 |
Why?
| Population Dynamics | 2 | 2012 | 136 | 0.110 |
Why?
| Urban Health | 1 | 2013 | 79 | 0.110 |
Why?
| Membrane Proteins | 1 | 2020 | 1108 | 0.110 |
Why?
| Emigrants and Immigrants | 1 | 2016 | 122 | 0.110 |
Why?
| Search Engine | 1 | 2013 | 10 | 0.110 |
Why?
| RNA-Binding Proteins | 1 | 2017 | 379 | 0.110 |
Why?
| Air Pollution | 1 | 2016 | 212 | 0.110 |
Why?
| Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
| Child | 15 | 2020 | 20721 | 0.110 |
Why?
| Nasal Mucosa | 1 | 2014 | 106 | 0.100 |
Why?
| Albuterol | 1 | 2013 | 104 | 0.100 |
Why?
| Hypersensitivity, Immediate | 1 | 2013 | 44 | 0.100 |
Why?
| Neanderthals | 1 | 2013 | 12 | 0.100 |
Why?
| Mutation | 5 | 2018 | 3692 | 0.100 |
Why?
| Chromosomes, Human, Pair 19 | 1 | 2012 | 23 | 0.100 |
Why?
| Carrier Proteins | 1 | 2017 | 731 | 0.100 |
Why?
| Principal Component Analysis | 1 | 2013 | 184 | 0.100 |
Why?
| Kallikreins | 1 | 2012 | 29 | 0.100 |
Why?
| Forced Expiratory Volume | 2 | 2013 | 509 | 0.100 |
Why?
| HLA-DQ beta-Chains | 1 | 2012 | 61 | 0.100 |
Why?
| Epigenesis, Genetic | 3 | 2024 | 616 | 0.100 |
Why?
| Biological Evolution | 2 | 2019 | 426 | 0.100 |
Why?
| Respiratory Function Tests | 2 | 2012 | 582 | 0.100 |
Why?
| Bronchodilator Agents | 1 | 2013 | 245 | 0.100 |
Why?
| United Kingdom | 2 | 2023 | 256 | 0.100 |
Why?
| Prostate-Specific Antigen | 1 | 2012 | 160 | 0.100 |
Why?
| Lung | 2 | 2016 | 3741 | 0.090 |
Why?
| HLA-B Antigens | 2 | 2022 | 62 | 0.090 |
Why?
| Tuberculosis | 1 | 2014 | 275 | 0.090 |
Why?
| History, 17th Century | 1 | 2011 | 14 | 0.090 |
Why?
| History, 15th Century | 1 | 2011 | 11 | 0.090 |
Why?
| Polynesia | 2 | 2021 | 3 | 0.090 |
Why?
| History, 18th Century | 1 | 2011 | 19 | 0.090 |
Why?
| Middle Aged | 11 | 2024 | 30893 | 0.090 |
Why?
| Mycobacterium tuberculosis | 1 | 2014 | 314 | 0.090 |
Why?
| Cluster Analysis | 3 | 2023 | 478 | 0.090 |
Why?
| History, 19th Century | 1 | 2011 | 57 | 0.090 |
Why?
| Cross-Sectional Studies | 1 | 2022 | 5040 | 0.090 |
Why?
| Chile | 2 | 2021 | 18 | 0.090 |
Why?
| Breast Neoplasms | 2 | 2014 | 2139 | 0.090 |
Why?
| Respiratory Sounds | 1 | 2011 | 120 | 0.090 |
Why?
| Estrogen Receptor alpha | 1 | 2012 | 134 | 0.090 |
Why?
| Body Height | 2 | 2023 | 192 | 0.090 |
Why?
| History, 21st Century | 1 | 2011 | 180 | 0.090 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 283 | 0.080 |
Why?
| South Africa | 3 | 2015 | 192 | 0.080 |
Why?
| Databases, Genetic | 2 | 2021 | 228 | 0.080 |
Why?
| History, 20th Century | 1 | 2011 | 291 | 0.080 |
Why?
| Cardiovascular Diseases | 1 | 2022 | 2018 | 0.080 |
Why?
| Genotyping Techniques | 2 | 2020 | 72 | 0.080 |
Why?
| Peru | 2 | 2022 | 53 | 0.080 |
Why?
| Vital Capacity | 1 | 2010 | 289 | 0.080 |
Why?
| Electronic Health Records | 3 | 2021 | 967 | 0.080 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1333 | 0.080 |
Why?
| Chromosomes, Human, Pair 8 | 2 | 2019 | 36 | 0.080 |
Why?
| Africa | 3 | 2017 | 98 | 0.080 |
Why?
| South America | 2 | 2020 | 56 | 0.070 |
Why?
| Life Style | 2 | 2022 | 459 | 0.070 |
Why?
| Americas | 2 | 2018 | 19 | 0.070 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 950 | 0.070 |
Why?
| Signal Transduction | 2 | 2019 | 4829 | 0.070 |
Why?
| Risk | 3 | 2018 | 852 | 0.070 |
Why?
| Ants | 1 | 2007 | 27 | 0.070 |
Why?
| Bayes Theorem | 2 | 2024 | 368 | 0.070 |
Why?
| Linguistics | 1 | 2007 | 27 | 0.070 |
Why?
| Odds Ratio | 3 | 2014 | 1022 | 0.070 |
Why?
| Whole Genome Sequencing | 2 | 2018 | 131 | 0.070 |
Why?
| Chromosomes, Human, Pair 17 | 2 | 2019 | 54 | 0.070 |
Why?
| Speech | 1 | 2007 | 74 | 0.070 |
Why?
| Human Genome Project | 2 | 2017 | 15 | 0.060 |
Why?
| Lung Diseases | 1 | 2012 | 722 | 0.060 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2022 | 3618 | 0.060 |
Why?
| Bias | 2 | 2019 | 195 | 0.060 |
Why?
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 485 | 0.060 |
Why?
| Child, Preschool | 6 | 2020 | 10373 | 0.060 |
Why?
| RNA | 1 | 2011 | 881 | 0.060 |
Why?
| Base Sequence | 3 | 2016 | 2134 | 0.060 |
Why?
| Argentina | 2 | 2015 | 14 | 0.060 |
Why?
| Phenethylamines | 1 | 2024 | 23 | 0.060 |
Why?
| Torsades de Pointes | 1 | 2024 | 21 | 0.060 |
Why?
| Cohort Studies | 4 | 2019 | 5369 | 0.060 |
Why?
| Microsatellite Repeats | 3 | 2011 | 161 | 0.060 |
Why?
| CpG Islands | 1 | 2024 | 152 | 0.050 |
Why?
| Polymorphism, Genetic | 2 | 2018 | 639 | 0.050 |
Why?
| Iran | 1 | 2023 | 38 | 0.050 |
Why?
| Los Angeles | 1 | 2023 | 63 | 0.050 |
Why?
| Geography | 2 | 2016 | 186 | 0.050 |
Why?
| Body Mass Index | 2 | 2023 | 2262 | 0.050 |
Why?
| Biology | 1 | 2024 | 83 | 0.050 |
Why?
| Caribbean Region | 2 | 2013 | 22 | 0.050 |
Why?
| Lipoprotein(a) | 1 | 2023 | 67 | 0.050 |
Why?
| Minisatellite Repeats | 1 | 2002 | 40 | 0.050 |
Why?
| Gene Regulatory Networks | 1 | 2025 | 281 | 0.050 |
Why?
| Factor X | 1 | 2022 | 25 | 0.050 |
Why?
| Factor VII | 1 | 2022 | 22 | 0.050 |
Why?
| Genes | 1 | 2002 | 226 | 0.050 |
Why?
| Age Factors | 2 | 2020 | 3117 | 0.050 |
Why?
| Blood Coagulation Factors | 1 | 2022 | 46 | 0.050 |
Why?
| Genome, Viral | 1 | 2022 | 127 | 0.050 |
Why?
| Epigenomics | 1 | 2022 | 111 | 0.050 |
Why?
| Genes, Recessive | 1 | 2021 | 75 | 0.050 |
Why?
| Loss of Function Mutation | 1 | 2021 | 39 | 0.050 |
Why?
| Inheritance Patterns | 1 | 2021 | 46 | 0.050 |
Why?
| Infant, Newborn | 3 | 2020 | 5687 | 0.050 |
Why?
| HLA-A Antigens | 1 | 2021 | 53 | 0.050 |
Why?
| Bronchi | 2 | 2014 | 240 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 425 | 0.050 |
Why?
| Quality Control | 1 | 2021 | 156 | 0.040 |
Why?
| Models, Statistical | 1 | 2025 | 625 | 0.040 |
Why?
| China | 1 | 2021 | 191 | 0.040 |
Why?
| Central America | 1 | 2020 | 21 | 0.040 |
Why?
| Sulfonamides | 1 | 2024 | 500 | 0.040 |
Why?
| Blood Proteins | 1 | 2022 | 236 | 0.040 |
Why?
| Infant | 3 | 2021 | 8913 | 0.040 |
Why?
| Ultrasonography | 1 | 2024 | 723 | 0.040 |
Why?
| Longitudinal Studies | 2 | 2020 | 2697 | 0.040 |
Why?
| Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.040 |
Why?
| Animals | 6 | 2024 | 34501 | 0.040 |
Why?
| Topography, Medical | 1 | 2019 | 12 | 0.040 |
Why?
| Sensitivity and Specificity | 1 | 2024 | 1820 | 0.040 |
Why?
| Classification | 1 | 2019 | 18 | 0.040 |
Why?
| Asia, Northern | 1 | 2018 | 1 | 0.040 |
Why?
| Aged, 80 and over | 3 | 2020 | 7040 | 0.040 |
Why?
| Mongolia | 1 | 2018 | 5 | 0.040 |
Why?
| Databases, Nucleic Acid | 1 | 2018 | 33 | 0.040 |
Why?
| Pharmacogenomic Testing | 1 | 2019 | 59 | 0.040 |
Why?
| Receptors, Natural Killer Cell | 1 | 2018 | 16 | 0.040 |
Why?
| Protein Interaction Domains and Motifs | 1 | 2019 | 137 | 0.040 |
Why?
| Hominidae | 1 | 2019 | 82 | 0.040 |
Why?
| Neoplasm Recurrence, Local | 1 | 2024 | 957 | 0.040 |
Why?
| Altitude | 1 | 2022 | 443 | 0.040 |
Why?
| Health Equity | 1 | 2019 | 79 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2019 | 530 | 0.040 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2018 | 70 | 0.040 |
Why?
| Reproducibility of Results | 2 | 2018 | 3023 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 857 | 0.040 |
Why?
| New York City | 1 | 2017 | 80 | 0.040 |
Why?
| DNA | 1 | 2024 | 1392 | 0.030 |
Why?
| Multigene Family | 1 | 2017 | 198 | 0.030 |
Why?
| Pilot Projects | 1 | 2022 | 1558 | 0.030 |
Why?
| DNA, Intergenic | 1 | 2016 | 24 | 0.030 |
Why?
| Prospective Studies | 3 | 2014 | 7043 | 0.030 |
Why?
| Musculoskeletal Diseases | 1 | 2017 | 69 | 0.030 |
Why?
| Health Status Disparities | 1 | 2019 | 248 | 0.030 |
Why?
| Genetic Heterogeneity | 1 | 2016 | 57 | 0.030 |
Why?
| Molecular Sequence Data | 2 | 2014 | 2818 | 0.030 |
Why?
| Residence Characteristics | 1 | 2019 | 324 | 0.030 |
Why?
| Cell Proliferation | 1 | 2024 | 2335 | 0.030 |
Why?
| Anthropometry | 1 | 2016 | 204 | 0.030 |
Why?
| Ligands | 1 | 2018 | 614 | 0.030 |
Why?
| Sexism | 1 | 2016 | 55 | 0.030 |
Why?
| Protein Conformation | 1 | 2019 | 853 | 0.030 |
Why?
| Membrane Transport Proteins | 1 | 2017 | 148 | 0.030 |
Why?
| Placenta | 1 | 2022 | 714 | 0.030 |
Why?
| Genetic Testing | 1 | 2018 | 427 | 0.030 |
Why?
| Gene Expression Regulation | 1 | 2025 | 2506 | 0.030 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2014 | 18 | 0.030 |
Why?
| HLA-DQ alpha-Chains | 1 | 2014 | 15 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2019 | 2041 | 0.030 |
Why?
| Crosses, Genetic | 1 | 2014 | 141 | 0.030 |
Why?
| San Francisco | 1 | 2013 | 52 | 0.030 |
Why?
| Mouth | 1 | 2014 | 82 | 0.030 |
Why?
| HeLa Cells | 1 | 2015 | 603 | 0.030 |
Why?
| Models, Molecular | 1 | 2019 | 1481 | 0.030 |
Why?
| HapMap Project | 1 | 2013 | 5 | 0.030 |
Why?
| Blood Glucose | 1 | 2023 | 2092 | 0.030 |
Why?
| Africa, Northern | 1 | 2013 | 4 | 0.030 |
Why?
| Databases, Factual | 1 | 2019 | 1268 | 0.030 |
Why?
| Mammography | 1 | 2014 | 143 | 0.030 |
Why?
| Sex Factors | 1 | 2019 | 1949 | 0.030 |
Why?
| Inflammation | 1 | 2024 | 2664 | 0.030 |
Why?
| Skin Tests | 1 | 2013 | 100 | 0.030 |
Why?
| Interleukin-13 | 1 | 2014 | 145 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2014 | 480 | 0.030 |
Why?
| Th2 Cells | 1 | 2014 | 167 | 0.030 |
Why?
| Hawaii | 1 | 2012 | 41 | 0.030 |
Why?
| Genome, Mitochondrial | 1 | 2012 | 27 | 0.030 |
Why?
| Protein Binding | 1 | 2019 | 2097 | 0.030 |
Why?
| HLA Antigens | 1 | 2014 | 235 | 0.030 |
Why?
| Income | 1 | 2013 | 189 | 0.030 |
Why?
| Air Pollutants | 1 | 2016 | 311 | 0.020 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2012 | 56 | 0.020 |
Why?
| Markov Chains | 1 | 2012 | 116 | 0.020 |
Why?
| Meta-Analysis as Topic | 1 | 2012 | 167 | 0.020 |
Why?
| Receptors, Estrogen | 1 | 2014 | 428 | 0.020 |
Why?
| Canada | 1 | 2012 | 345 | 0.020 |
Why?
| Boston | 1 | 2011 | 86 | 0.020 |
Why?
| Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 17 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2012 | 386 | 0.020 |
Why?
| Insurance, Health | 1 | 2013 | 271 | 0.020 |
Why?
| Angola | 1 | 2011 | 1 | 0.020 |
Why?
| Mozambique | 1 | 2011 | 6 | 0.020 |
Why?
| Educational Status | 1 | 2013 | 470 | 0.020 |
Why?
| Africa South of the Sahara | 1 | 2011 | 39 | 0.020 |
Why?
| Microfilament Proteins | 1 | 2012 | 125 | 0.020 |
Why?
| North America | 1 | 2011 | 289 | 0.020 |
Why?
| Culture | 1 | 2011 | 125 | 0.020 |
Why?
| Allergens | 1 | 2013 | 383 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2011 | 423 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 304 | 0.020 |
Why?
| Molecular Chaperones | 1 | 2011 | 172 | 0.020 |
Why?
| Time Factors | 1 | 2020 | 6503 | 0.020 |
Why?
| Pregnancy | 1 | 2022 | 6297 | 0.020 |
Why?
| Reference Values | 1 | 2010 | 780 | 0.020 |
Why?
| Family | 1 | 2013 | 642 | 0.020 |
Why?
| Tanzania | 1 | 2008 | 42 | 0.020 |
Why?
| Logistic Models | 1 | 2013 | 1975 | 0.020 |
Why?
| Hypersensitivity | 1 | 2011 | 249 | 0.020 |
Why?
| Social Behavior | 1 | 2011 | 287 | 0.020 |
Why?
| Inbreeding | 1 | 2007 | 17 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2014 | 1182 | 0.020 |
Why?
| Linear Models | 1 | 2010 | 816 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 2014 | 1415 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2014 | 3160 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2008 | 475 | 0.020 |
Why?
| Transcription Factors | 1 | 2014 | 1631 | 0.020 |
Why?
| Prevalence | 1 | 2013 | 2549 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1693 | 0.020 |
Why?
| Reproduction | 1 | 2007 | 201 | 0.020 |
Why?
| Smoking | 1 | 2012 | 1463 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2011 | 2736 | 0.010 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2002 | 29 | 0.010 |
Why?
| DNA Fragmentation | 1 | 2002 | 43 | 0.010 |
Why?
| Nucleic Acid Amplification Techniques | 1 | 2002 | 32 | 0.010 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 2002 | 41 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2013 | 5346 | 0.010 |
Why?
| Fluorescent Dyes | 1 | 2002 | 313 | 0.010 |
Why?
| Mice | 1 | 2013 | 16579 | 0.010 |
Why?
|
|
Gignoux's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|